E
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014
E
Sedgemoor Entrance

Healthcare Innovation in Action: Designing for Dementia

Can design make a difference to those with dementia? Liverpool City Council's award-winning Sedgemoor Dementia Support Centre shows how design innovation can stimulate memories and offer improved quality of life.

April 28, 2014
E
Everton in the Community

Everton FC leads the way in community dementia support

Everton FC and Mersey Care NHS Trust use football memorabilia and activities at Goodison Park to stimulate memories and support members of the local community with dementia.

April 23, 2014
E
Source: Roche

Update on anti-PD-L1 cancer immunotherapy

Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?

January 22, 2014
E
CAR T Cells

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014
E
FDA Cancer Related NME Approvals 2012

2012 was a Grand Cru year for the FDA with 39 NMEs approved

FDA approved 39 new molecular entities in 2012. This is the highest number in the last 10 years. However, approval rate is not a surrogate benchmark for the state of innovation given that it can take several years to bring a new drug or biologic to market.

January 2, 2013
E
Early bionic eye prototype drawing - Image courtesy of Bionics Institute

Innovation in Action: helping people to see again

FDA approves first artificial retina prosthesis, the Argus II from Second Sight. This is not a bionic eye. To date, only crude images can be detected. There is no dramatic restoration of sight or vision, instead retinal prostheses currently only offer the ability to detect light and large shapes. Several companies and research groups including Bionic Vision Australia are working on innovative retinal prostheses that aim to restore some vision.

September 17, 2012
E
Credit: Caltech and Harvard University

Creating an artificial jellyfish to model the human heart

Creation of an artificial jellyfish advances the potential to reverse engineer the human heart

August 20, 2012
E
listening-ear

The Potential of Gene Therapy to Restore Hearing Loss

Restoration of hearing in mice by gene transfer is a major breakthrough

August 14, 2012
E
Science Translational Medicine Cover May 16

Repetitive brain injury from high impact sports generates similar pathophysiology to traumatic brain injury in soldiers blown up by IEDs

Several retired American Football stars have ended up with chronic traumatic encephalophy (CTE). It’s similar to Alzheimer’s disease in that the brain ends up with neurofibrillary tangles. CTE has also been seen in soldiers who have experienced blast induced traumatic brain injury (bTBI) from improvised explosive devices (IEDs)

May 21, 2012
E
Drug Development Pipeline

TEDMED 2012: Francis Collins on how to brings drugs to market faster

It can take 14 years of research and the screening of 10,000 compounds to bring 1 new drug to market.

May 18, 2012
E
Participant S3 drinking froma bottle using the DLR robotic arm

Innovation in Neurotechnology: how a paralyzed person uses thoughts to control a robotic arm

A tetraplegic (all four limbs paralyzed) is able to use her mind to control a robotic arm, 15 years after she became completely paralyzed & unable to speak.

May 16, 2012
E
Winter in Malta

A personal perspective on Alzheimer’s: my mother doesn’t dance anymore

I have a personal interest in Alzheimer’s disease. It’s an area where innovation needs to catch up with demand for treatment and therapies, not to treat it when it’s happened – it’s too late to untangle the damage, but to delay it’s occurrence in those at risk.

March 9, 2012
E
MicroCHIPS Drug Delivery Device

Implanted Wireless Microchip offers Osteoporosis Drug Delivery that improves patient Quality of Life

Robert Farra of MicroCHIPS, Inc. and research collaborators, describe a first-in-human testing of a wirelessly controlled drug delivery microchip.

February 20, 2012
E
Children's Hospital Boston Innovation Acceleration Program

Today is Innovation Day at Childrens Hospital Boston #iDay

Children’s Hospital Boston has an Innovation Acceleration Program focused on supporting “clinical care that impacts patients around the world.”

February 14, 2012
E
Nature-Medicine-November-2011-Cover

Blocking Sema4D may be a new osteoporosis target

Research published in the November 2011 issue of the journal Nature Medicine has highlighted a new potential target for osteoporosis drug development that acts on osteoblasts and promotes bone formation.

November 10, 2011
E
Yankee-Lou-Gehrig-scores-head-first-in-1925

Discovering the cause of Lou Gehrig’s disease

Scientists from Northwestern University in Chicago report findings that could help develop drugs for patients with Amyotrophic Lateral Sclerosis (ALS), more commonly known as Lou Gehrig’s disease.

August 31, 2011
E
Aug-11-Cover-of-Nature

Can we halt memory loss as we get older?

New research offers the hope that in the future we may be able to reverse or slow-down the age-related memory loss and cognitive defects we would otherwise experience.

August 26, 2011
E
forbes_082211

Innovation – should companies take bigger risks and outsource pharma R&D?

"Rather than do research in house, companies should close their labs and outsource the work to tiny, nimble startups that can explore bigger, crazier ideas.”

August 3, 2011
E
Biohybridized-Neural-Interface-300x201

How we may be able to rebuild The Six Million Dollar Man

The Six Million Dollar Man was fiction, but it is becoming closer to reality as a result of new research into how artificial limbs can integrate with human tissues

July 11, 2011
E
Miami Beach

How does sunburn cause pain?

Research by John Dawes and colleagues at King’s College London & University College London has shed new light on how sunburn causes pain.

July 8, 2011
E
seifaliancrowley_crop-150x150

Regenerative Medicine: Tissue Engineered Airway Transplant

Researchers from University College London led by Prof. Alexander Seifalian designed and built a polymer based nanocomposite tracheal scaffold, which was then seeded with the patient’s own stem cells.

July 7, 2011
E
F1.medium-235x300

Science Translational Medicine on Innovation – part 1

With an image of Rodin’s bronze “The Thinker” on its cover suggesting deep thought and insight, the journal "Science Translational Medicine" analyzes the state of innovation.

July 7, 2011
E
Cover-of-Nature-7-April-2011

Will the future offer artificial retina transplants?

A Nature article shows, for the first time, the ability to generate a three-dimensional culture of neural retinal tissue from mouse embryonic stem (ES) cells.

April 29, 2011
E
Michael-J.-Fox-Foundation-Logo

The future of Parkinson’s disease, part 2 of an interview with Dr Todd Sherer, Chief Program Officer, Michael J Fox Foundation

"The understanding of the genetics of Parkinson’s will certainly form the building blocks of some future breakthroughs. Now that we have very tangible therapeutic targets that we know can cause Parkinson’s, it makes a much more rational directed drug development program."

April 8, 2011
E
Michael-J.-Fox-Foundation

Making a difference to Parkinson’s Disease Research, an interview with Dr Todd Sherer, Michael J Fox Foundation

"The goal of the foundation, the goal of all the research that we are supporting is to develop new therapies for Parkinson’s disease patients."

March 31, 2011
E
Nature-Cover-March-17-2011

Of Mice and Men

The March 17, 2011 edition of Nature, highlights how innovative preclinical animal models are having an impact on drug development.

March 25, 2011
E
EAU 2011 Vienna

Technology Innovation – the challenges and opportunities with robotic surgery

At the European Association of Urology (EAU) annual congress in Vienna, Associate Professsor Axel Merseburger from Hannover in Germany discussed some of the challenges with robotic surgery for prostatectomy or partial nepthrectomy.

March 19, 2011
E
LLNL Artificial Retina Video Screen Shot

Argus III is the next generation of artificial retina from Lawrence Livermore National Laboratory

Lawrence Livermore National Laboratory (LLNL) have produced an excellent video about their manufacturing of the Argus™ III artificial retina.

March 14, 2011
E
collaboratormapthumb

Artificial Retina Project shows power of collaboration to bring new products to market

The Artificial Retina Project is a case study on the success of collaboration.

March 14, 2011
E
second sight logo

New artificial retina restores some visual perception and improves autonomy

Detecting a door or a window may not be a big deal for all of us with normal vision, but for those who lose their sight, e.g. through retinitis pigmentosa (RP), a new "artificial retina" now provides hope of a better quality of life.

March 8, 2011
E
romosozumab NEJM press release

Targeting Sclerostin in Osteoporosis

Sclerostin is a protein produced by osteocytes within bone that inhibits bone formation. It is thought to pass through the surface of bone where it acts on osteoblasts (cells responsible for bone formation). There it binds to low-density lipoprotein receptors and inhibits the Wnt/beta-catenin signaling involved in bone mass regulation. Promising phase 2 trial data for a novel sclerostin inhibitor, romosozumab (AMG 785), in osteoporosis has just been published in the New England Journal of Medicine.

March 10, 2011
E
Chemical-Structure-of-odanacatib-MK-0822.-Image-Copyright-Merck

Merck’s cathepsin-K inhibitor odanacatib in osteoporosis

Cathepsin-K inhibition is a novel approach to osteoporosis treatment and Merck's odanacatib is leading the way in this new class of drugs.

February 11, 2011
E
Nature Reviews Drug Discovery

Emerging drugs in development for Osteoporosis

The market opportunity for osteoporosis remains significant, affecting 44 million people in the United States over the age of 50, resulting in healthcare costs in excess of $15 billion a year.

February 8, 2011
E
1.cover_

New research points to role of Cystic Fibrosis Transmembrane Conductance Regulator Signaling in Emphysema

Developing drugs that target cystic fibrosis transmembrane regulator (CFTR) protein and mediate ceramide may have an important role to play in the treatment of emphysema

January 10, 2011